A study led by the National Cardiovascular Center in Japan investigated the potential benefits of dapagliflozin, a medication for type 2 diabetes, in patients with chronic heart failure and diabetes.
The two-year study with 294 participants suggested that while dapagliflozin, a diabetes drug, did not significantly reduce kidney damage markers, it showed promise in lowering cardiovascular events.
The study, published in eClinicalMedicine, is the first to indicate that dapagliflozin, particularly at a 5 mg dose, may effectively reduce cardiovascular events in patients with chronic heart failure and type 2 diabetes.
While dapagliflozin did not demonstrate a significant reduction in urinary albumin excretion, which was the primary endpoint, it did show promise in reducing cardiovascular events.
READ MORE: Insufficient sleep threatens heart health
The secondary endpoint, which measured cardiovascular events (including cardiovascular death, hospitalization for cardiovascular events, and additional heart failure medication), was lower in the dapagliflozin group compared to the standard treatment group.
These findings could impact treatment strategies for individuals with both conditions, providing valuable insights for clinical practice.
This drug is available in Pakistan under the names Dapa (Hilton Pharma) and Xiga (CCL Pharma) in 10 mg and 5 mg variants, with a price range of Rs. 270 to Rs. 400.
